Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes.

[1]  A. Ruskova,et al.  Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes. , 2019, Pathology.

[2]  G. Schuurhuis,et al.  Can we incorporate MRD assessment into clinical practice in AML? , 2019, Best practice & research. Clinical haematology.

[3]  Junmin Li,et al.  Identifying leukemia‐associated immunophenotype‐based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance , 2019, American journal of hematology.

[4]  Hao Jiang,et al.  Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations , 2019, Leukemia & lymphoma.

[5]  V. V. D. van der Velden,et al.  Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible? , 2019, Leukemia research.

[6]  R. Hills,et al.  Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Torsten Haferlach,et al.  Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. , 2018, Blood.

[8]  K. Jahnukainen,et al.  Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO‐AML 2004 study , 2016, British journal of haematology.

[9]  E. Estey,et al.  Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Grimwade,et al.  Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? , 2014, Blood.

[11]  J. Jorgensen,et al.  Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future , 2014, Bone Marrow Transplantation.

[12]  Robert K Hills,et al.  Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  V. V. D. van der Velden,et al.  Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting , 2013, Blood Cancer Journal.

[14]  Todd A Alonzo,et al.  Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. , 2012, Blood.

[15]  J. Dongen,et al.  Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol , 2010, Leukemia.

[16]  Xiao Li,et al.  Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS‐based immunophenotypes , 2010, British journal of haematology.

[17]  Wolfgang Kern,et al.  Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes , 2009, Haematologica.

[18]  L. Malcovati,et al.  Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study , 2009, Haematologica.

[19]  J. Gratama,et al.  Flow cytometric differential of leukocyte populations in normal bone marrow: Influence of peripheral blood contamination1 , 2009, Cytometry. Part B, Clinical cytometry.

[20]  David Gillis,et al.  The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. , 2009, American journal of clinical pathology.

[21]  David Gillis,et al.  Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. , 2008, American journal of clinical pathology.

[22]  G. Schuurhuis,et al.  MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia , 2004, Leukemia.

[23]  W. Hiddemann,et al.  Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. , 2003, Haematologica.